Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387214 | 1.00 | PAOX (0.55) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL1404033 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL1403872 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL5880368 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL1619627 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL1403846 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL1619610 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL20231224 | 0.98 | PAOX (0.59) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL8866 | 0.92 | PAOX (0.52) | PAOXSIGMAR1ALDH1A1USP2HPGD | |
| SCHEMBL3427480 | 0.91 | PAOX (0.48) | PAOXSIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | claimed |
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | claimed |
| US-6197844-B1 | Floor finish compositions | 3M INNOVATIVE PROPERTIES COMPANY | 2001-03-06 | — | — | US | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | PAOX 2038/4885SIGMAR1 511/4885ALDH1A1 3862/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | PAOX 3196/4885SIGMAR1 158/4885ALDH1A1 2449/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | PAOX 2642/4885SIGMAR1 183/4885ALDH1A1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.